Malaria and HIV Supply Chains Face a New Disruption

A U.S.-backed supply program that delivered more than $5 billion of HIV and malaria products to 90 countries from 2016 to 2024 is being dismantled on an accelerated timeline, according to an internal email reported by Reuters and reviewed through a WHBL republication.

The report said the United States has begun shifting away from the Global Health Supply Chain Program run by contractor Chemonics, with staff in 17 African countries and Haiti told to stop implementing the program by May 30. The email, according to Reuters, warned of “immediate risks to service continuity” if the transition is rushed or incomplete.

The timing matters because global health procurement does not move at consumer speed. Reuters reported that two sources familiar with talks said an earlier transition discussion had focused on November 2027, and that ordering products for hard-to-reach areas can take up to a year. Several sources told the news agency that the new timetable could create gaps in medicines and prevention tools.

The current change follows an earlier shock. Reuters said the program was halted when international aid was frozen at the start of President Donald Trump’s term last year, leaving supplies stranded in ports and warehouses before some work resumed under waivers for life-saving products.

The April 8 Albis scan found African and European coverage treating the latest changes as a direct health-systems risk, while the story remained less visible across large parts of Asia, Latin America and the Middle East. That gap matters because clinics do not experience a procurement overhaul as an abstract debate over contractors. They experience it as missing pediatric malaria drugs, delayed HIV prevention deliveries and tighter inventory control at facilities already under pressure.

Reuters said the U.S. is discussing future use of the Global Fund’s supply platform to procure and deliver health products. The Global Fund already manages around $2 billion a year in supplies for AIDS, tuberculosis and malaria, according to the report. But Reuters said the organization declined to comment and the State Department did not answer specific questions on whether those talks were under way.

The administration has framed the move as part of a broader “America First” redesign of global health aid. Reuters said a State Department spokesperson described the previous model as bloated and inefficient and said the U.S. would use pooled mechanisms to buy supplies at lower prices from private manufacturers.

Health specialists quoted in the report focused on speed rather than ideology. Five sources told Reuters that shortages or service gaps were likely in some countries if the handover moved too quickly. That warning aligns with the Albis scan, which said financing changes were already becoming medicine gaps on the ground and could hit children and vulnerable patients first.

The regional framing is blunt. In donor capitals, the argument is about contracting, budgets and who should manage delivery. In African health systems, the issue is whether a community clinic has test kits, bed nets, antiretrovirals and malaria treatment when the next patient arrives.

Because malaria and HIV programs depend on recurring procurement cycles, even a short disruption can ripple for months. Orders missed now can collide with rainy-season malaria demand or interrupt prevention campaigns already scheduled around local disease patterns.

The next deadline is May 30, when U.S. country teams were told to cease implementation under the reported plan. Whether Washington slows the transition, formalizes a handover to pooled procurement, or pushes ahead unchanged will determine whether this remains an administrative shake-up or becomes a broader medicine shortage.